Gossamer Bio, Inc.

• Gossamer Bio, Inc. Estimates – NASDAQ:GOSS
  TradingView · 23 Oct 2026
• Gossamer Bio Appoints Greg Ciongoli to Board of Directors
  The National Law Review · 18 Oct 2026
• Gossamer Bio files FDA application. Gossamer Bio stock sits at USD 54.3 million market value.
  AD HOC NEWS · 16 Oct 2026
• Chardan initiates Gossamer Bio stock with buy on PAH therapy potential
  Investing.com · 13 Oct 2026
• GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS)
  ChartMill · 10 Oct 2026
• Form 13D/A Gossamer Bio For: 8 October By Investing.com
  Investing.com UK · 09 Oct 2026
• Form 13D/A Gossamer Bio For: 28 September By Investing.com
  Investing.com UK · 29 Sep 2026
• Gossamer Bio files FDA application for seralutinib in pulmonary arterial hypertension
  Indian Pharma Post · 28 Sep 2026
• Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split
  TradingView · 28 Sep 2026
• Form 4 Gossamer Bio Inc For: 25 September By Investing.com
  Investing.com UK · 25 Sep 2026
• Gossamer Bio submits NDA for seralutinib in PAH treatment By Investing.com
  Investing.com India · 24 Sep 2026
• Gossamer Bio stock falls 5.99 percent after FDA filing
  ad-hoc-news.de · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →